Original paper

Cost-Effectiveness Analysis of Landiolol, an Ultrashort-Acting Beta-Blocker, for Prevention of Postoperative Atrial Fibrillation for the Germany Health Care System

Volume: 34, Issue: 4, Pages: 888 - 897
Published: Apr 1, 2020
Abstract
ObjectivesLandiolol is an ultrashort-acting beta-blocker with high beta-1 receptor affinity and less blood pressure–lowering properties than other beta-blockers available for intravenous use in Germany. The present analysis aimed to determine whether perioperative treatment with landiolol in cardiac surgical patients is cost-effective under the conditions of the German Diagnosis-Related Groups health cost reimbursement system.DesignOn the basis...
Paper Details
Title
Cost-Effectiveness Analysis of Landiolol, an Ultrashort-Acting Beta-Blocker, for Prevention of Postoperative Atrial Fibrillation for the Germany Health Care System
Published Date
Apr 1, 2020
Volume
34
Issue
4
Pages
888 - 897
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.